Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBT (2016 - 2025)

Iovance Biotherapeutics has reported EBT over the past 13 years, most recently at -$71.7 million for Q4 2025.

  • Quarterly results put EBT at -$71.7 million for Q4 2025, up 6.86% from a year ago — trailing twelve months through Dec 2025 was -$393.0 million (down 4.81% YoY), and the annual figure for FY2025 was -$393.0 million, down 4.81%.
  • EBT for Q4 2025 was -$71.7 million at Iovance Biotherapeutics, up from -$93.7 million in the prior quarter.
  • Over the last five years, EBT for IOVA hit a ceiling of -$71.7 million in Q4 2025 and a floor of -$118.1 million in Q4 2023.
  • Median EBT over the past 3 years was -$107.2 million (2023), compared with a mean of -$101.3 million.
  • Biggest five-year swings in EBT: skyrocketed 34.82% in 2024 and later fell 11.27% in 2025.
  • Iovance Biotherapeutics' EBT stood at -$118.1 million in 2023, then skyrocketed by 34.82% to -$77.0 million in 2024, then increased by 6.86% to -$71.7 million in 2025.
  • The last three reported values for EBT were -$71.7 million (Q4 2025), -$93.7 million (Q3 2025), and -$109.7 million (Q2 2025) per Business Quant data.